Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Subscribe To Our Newsletter & Stay Updated
